Raltegravir (Isentress, Merck) has been approved by the FDA for use with other antiretroviral drugs for the treatment of HIV-1 infection for children and adolescents who are aged 2 to 18 years. This drug is an HIV integrase strand-transfer inhibitor which works by slowing the spread of HIV in the body.














